CSB 2.012 Note961.20 (2) (eqm) Lemborexant.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 5-18-20; CR 20-076: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787. CSB 2.012 NoteCSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section 961.14 (4) (t) 4., Stats., is created to read: CSB 2.012 Note961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.012 Note(2) Section 961.22 (7) is repealed.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-077: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.012 NoteCSB 2.76 Addition of norfentanyl to schedule II. (1) Section 961.16 (8) (b), Stats., is renumbered 961.16 (8) (b) (intro.) and amended to read:
CSB 2.012 Note961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:
CSB 2.012 Note1. 4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.
CSB 2.012 Note2. N-phenyl-N-(piperidin-4-yl)propionamide, commonly known as norfentanyl.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.012 NoteCSB 2.77 Scheduling of flualprazolam. Section 961.20 (2) (ef), Stats., is created to read: CSB 2.012 Note961.20 (2) (ef) Flualprazolam;
CSB 2.012 HistoryHistory: EmR1037: emerg. cr., eff. 10-27-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787. CSB 2.012 NoteCSB 2.78 Addition of crotonyl fentanyl to schedule I. Section 961.14 (2) (nd) 9m., Stats., is created to read: CSB 2.012 Note961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11-23-20; CR 22-011: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810. CSB 2.012 NoteCSB 2.79 Addition of remimazolam to schedule IV. Section 961.20 (2) (mo), Stats., is created to read: CSB 2.012 Note961.20 (2) (mo) Remimazolam;
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11-23-20; CR 22-014: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810. CSB 2.012 NoteCSB 2.80 Scheduling of oliceridine. Section 961.16 (3) (ta), Stats., is created to read: CSB 2.012 Note961.16 (3) (ta) Oliceridine;
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2020 No. 780, eff. 12-14-20; CR 21-098: cr. Register August 2022 No. 800, eff. 9-1-22. CSB 2.012 NoteCSB 2.81 Addition of brorphine to schedule I. Section 961.14 (2) (et), Stats., is created to read: CSB 2.012 Note961.14 (2) (et) Brorphine;
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2021 No. 785, eff. 4-26-21; correction made under s. 35.17, Stats., Register May 2021 No. 785; CR 22-016: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810. CSB 2.012 NoteCSB 2.82 Addition of Serdexmethylphenidate to schedule IV. Section 961.20 (2m) (em), Stats., is created to read: CSB 2.012 Note961.20 (2m) (em) Serdexmethylphenidate.